Bontelvia 35 mg FC tablet)
PDF Leaflet Revision Date: 13 December 2019
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of osteoporosis in postmenopausal women and males.
Dosage (summary)
One 35 mg tablet orally once a week.
Onset of Action / Duration
Onset: ~1 hour, Duration: Not specified
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Aspirin
- NSAIDs
- Hormone replacement therapy
- Polyvalent cations
Contraindications
- Hypersensitivity to risedronate
- Hypocalcaemia
- Advanced renal impairment
- Pregnancy
- Lactation
Common side effects
- Dyspepsia
- Nausea
- Constipation
- Diarrhoea
- Musculoskeletal pain
Counselling Points
- Take with a full glass of water
- Remain upright for 30 mins after taking
- Avoid food/drinks containing polyvalent cations around dosing time
Serious warnings
- Risk of oesophageal reactions
- Osteonecrosis of the jaw
- Atypical femur fractures
Important Disclaimer
The Bontelvia 35 mg FC tablet) professional information leaflet below is the property of Macleods Pharmaceutical Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
